FIBROCELL SCIENCE, INC. (NASDAQ:FCSC) Files An 8-K Other EventsItem 8.01 Other Events.
On December 11, 2018, Fibrocell Science Inc. (the "Company") issued a press release announcing that EB Research Partnership, Inc. and Epidermolysis Bullosa Medical Research Foundation have invested $900,000 to help further the progress of FCX-007, the Company’s gene therapy candidate for the treatment of recessive dystrophic epidermolysis bullosa, a rare, devastating, blistering skin disease with high mortality. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits
|
Exhibit No. |
Description |
|
Press Release dated December 11, 2018.
|
Fibrocell Science, Inc. ExhibitEX-99.1 2 ex991finalebrpebmrf.htm EXHIBIT 99.1 ex991finalebrpebmrf Fibrocell Receives $900,…To view the full exhibit click here
About FIBROCELL SCIENCE, INC. (NASDAQ:FCSC)
Fibrocell Science, Inc. is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related. It is investigating the indication in a Phase II clinical trial. Its gene-therapy product candidate, FCX-007, is in pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Its gene-therapy product candidate, FCX-013, is in pre-clinical development for the treatment of linear scleroderma. Its product, LAVIV (azficel-T), is indicated for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. A third gene-therapy program is focused on the treatment of arthritis. Its product, LAVIV (azficel-T), is focused on improving the appearance of nasolabial fold wrinkles in adults.
